Evidence map›Paper›PMID 29215864›Full record

ArticleACS nano2018

Platinum Nanocatalyst Amplification: Redefining the Gold Standard for Lateral Flow Immunoassays with Ultrabroad Dynamic Range.

Colleen N Loynachan, Michael R Thomas, Eleanor R Gray, Daniel A Richards, Jeongyun Kim, Benjamin S Miller, Jennifer C Brookes, Shweta Agarwal, Vijay Chudasama, Rachel A McKendry and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 398 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Colleen N LoynachanDepartment of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London , London SW7 2BP, U.K.ORCID 0000-0001-5617-4091
Michael R ThomasDepartment of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London , London SW7 2BP, U.K.ORCID 0000-0001-7795-9648
Eleanor R GrayORCID 0000-0002-6515-839X
Daniel A RichardsDepartment of Chemistry, University College London , 20 Gordon Street, London WC1H 0AJ, U.K.
Jeongyun KimDepartment of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London , London SW7 2BP, U.K.
Benjamin S MillerORCID 0000-0003-3032-018X
Jennifer C Brookes
Shweta AgarwalDepartment of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London , London SW7 2BP, U.K.
Vijay ChudasamaDepartment of Chemistry, University College London , 20 Gordon Street, London WC1H 0AJ, U.K.
Rachel A McKendryORCID 0000-0003-2018-6829
Molly M StevensDepartment of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London , London SW7 2BP, U.K.ORCID 0000-0002-7335-266X
Imperial College London · GBUniversity College London · GB

Funding

European Research Council 616417Medical Research Council MR/P024378/1
6 · The paper itself

Abstract

Paper-based lateral flow immunoassays (LFIAs) are one of the most widely used point-of-care (PoC) devices; however, their application in early disease diagnostics is often limited due to insufficient sensitivity for the requisite sample sizes and the short time frames of PoC testing. To address this, we developed a serum-stable, nanoparticle catalyst-labeled LFIA with a sensitivity surpassing that of both current commercial and published sensitivities for paper-based detection of p24, one of the earliest and most conserved biomarkers of HIV. We report the synthesis and characterization of porous platinum core-shell nanocatalysts (PtNCs), which show high catalytic activity when exposed to complex human blood serum samples. We explored the application of antibody-functionalized PtNCs with strategically and orthogonally modified nanobodies with high affinity and specificity toward p24 and established the key larger nanoparticle size regimes needed for efficient amplification and performance in LFIA. Harnessing the catalytic amplification of PtNCs enabled naked-eye detection of p24 spiked into sera in the low femtomolar range (ca. 0.8 pg·mL

Indexed as

Point-of-Care TestingAntibodies, ImmobilizedCatalysisEquipment DesignGoldHIVHIV Core Protein p24HIV InfectionsHumansImmunoassayMetal NanoparticlesPlatinumPorosityAntibodies, ImmobilizedGoldHIV Core Protein p24Platinumbiorthogonal chemistrybroad dynamic rangeenzyme mimicHIV detectionlateral flow immunoassaynanobodiespoint-of-careporous platinum core−shell nanoparticles

Identifiers

PMID29215864
PMCPMC5785759
OpenAlexW2773898323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.